Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple dopamine receptors and behavior.

J N Joyce

    Neuroscience and Biobehavioral Reviews
    |January 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Atypical antipsychotics and antiparkinsonian agents likely treat conditions like schizophrenia and Parkinson's disease through multiple dopamine receptor interactions, not just one. Other pharmacological factors are key to their unique effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis.

    Brain : a journal of neurology·2007
    Same author

    Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia.

    Neurobiology of aging·2006
    Same author

    Age-related changes in nigrostriatal dopaminergic function are accentuated in +/- brain-derived neurotrophic factor mice.

    Neuroscience·2004
    Same author

    Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors.

    Brain research·2002
    Same author

    Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs.

    Pharmacology & therapeutics·2001
    Same author

    Thalamo-cortical afferents control transient expression of the dopamine D(3) receptor in the rat somatosensory cortex.

    Cerebral cortex (New York, N.Y. : 1991)·2001

    Area of Science:

    • Neuropharmacology
    • Movement Disorders
    • Psychiatric Disorders

    Background:

    • Dopamine (DA) agonists and antagonists treat schizophrenia, Huntington's chorea, and Parkinson's disease, primarily via striatal DA receptors.
    • Classical drugs often cause extrapyramidal side effects (EPS), unlike newer atypical antipsychotics and antiparkinsonian agents.

    Purpose of the Study:

    • Investigate the characteristics of atypical agents responsible for their unique behavioral profiles.
    • Examine the role of dopamine receptor subtypes in the therapeutic actions of these drugs.

    Main Methods:

    • Review of existing literature on dopamine receptor pharmacology and drug interactions.
    • Analysis of animal models for assessing drug profiles and clinical relevance.

    Related Experiment Videos

    Main Results:

    • Evidence suggests atypical agents interact with multiple dopamine receptor subtypes.
    • Therapeutic effects are unlikely to stem from interaction with a single DA receptor subtype alone.

    Conclusions:

    • Other pharmacological properties, beyond specific dopamine receptor subtype interactions, are critical for the distinct effects of atypical agents.
    • Animal models are valuable for understanding drug profiles and their clinical applicability.